News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Anacor Pharmaceuticals, Inc. Files for $57.5 Million IPO



9/4/2007 6:24:11 AM

PALO ALTO, Calif., Aug. 31 /PRNewswire/ -- Anacor Pharmaceuticals announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of shares of its common stock. All of the shares in the proposed offering are being sold by Anacor.

The underwriters of the offering will be Morgan Stanley & Co. Incorporated as sole book runner, Cowen and Company, LLC as co-lead, and Pacific Growth Equities, LLC and Needham & Company, LLC as co-managers. The number of shares to be offered and the price range for the offering have not yet been determined.

The offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus relating to the offering may be obtained from Morgan Stanley & Co. Incorporated by emailing prospectus@morganstanley.com, or by contacting the prospectus department at Morgan Stanley & Co. Incorporated, 180 Varick, New York, NY 10014, telephone (866) 718-1649.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. This registration statement is available on the Securities and Exchange Commission website at http://edgar.sec.gov. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform. Anacor has focused initially on developing topical applications of its compounds to treat fungal, bacterial and inflammatory diseases. Anacor's most advanced product candidate is AN2690, a novel topical antifungal in development for the treatment of toenail onychomycosis, which is a fungal infection of the nail and nail bed. Anacor entered into a worldwide license, development and commercialization agreement for AN2690 with Schering-Plough for all indications including the treatment of onychomycosis. Pending discussions with the FDA, Anacor anticipates that Schering-Plough will initiate Phase 3 clinical trials for AN2690 in onychomycosis in 2008. In addition, Anacor has a portfolio of other topical product candidates in development for the treatment of psoriasis, gingivitis, acne, vaginal candidiasis and tinea pedis.

Anacor Pharmaceuticals

CONTACT: Anne Bowdidge of Anacor Pharmaceuticals, +1-650-859-1108; orDaryl Messinger of WeissComm Partners, Inc., +1-415-946-1062,daryl@weisscommpartners.com, for Anacor Pharmaceuticals


Read at BioSpace.com
Read at Reuters


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES